引用本文: | 姜爱雯,杜佩珊,汤建华,石金铮,刘云宁,张鹤鸣.阿昔莫司联合氯吡格雷对高脂血症患者血脂及颈动脉斑块的影响[J].中国现代应用药学,2020,37(5):600-603. |
| JIANG Aiwen,DU Peishan,TANG Jianhua,SHI Jinzheng,LIU Yunning,ZHANG Heming.Effect of Acipimox Combined with Clopidogrel on Blood Lipid and Carotid Plaque in Patients with Hyperlipidemia[J].Chin J Mod Appl Pharm(中国现代应用药学),2020,37(5):600-603. |
|
摘要: |
目的 探讨阿昔莫司联合氯吡格雷治疗高脂血症并颈动脉斑块的临床疗效。方法 选取高脂血症并颈动脉斑块患者66例,随机分为阿昔莫司组和阿昔莫司+氯吡格雷组。阿昔莫司组给予阿昔莫司0.25 g,口服,bid;阿昔莫司+氯吡格雷组给予阿昔莫司0.25 g,口服,bid+氯吡格雷75 mg,口服,qd。2组患者疗程均为8周,观察2组患者治疗前后血浆总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、颈动脉内膜中层厚度(IMT)、血流变参数、肿瘤坏死因子-α(TNF-α)、白细胞介素-1(IL-1)和白细胞介素-6(IL-6)情况。结果 治疗前2组患者TC、TG、HDL-C、LDL-C、IMT、血流变参数、TNF-α、IL-1和IL-6比较,差异均无统计学意义。治疗后2组患者TC、LDL-C、颈动脉斑块面积、血浆纤维蛋白原、TNF-α、IL-6均显著低于同组治疗前,且阿昔莫司+氯吡格雷组显著低于阿昔莫司组,差异有统计学意义(P<0.05)。2组患者对IMT均有改善作用,但与治疗前无显著性差异。结论 阿昔莫司联合氯吡格雷对高脂血症患者血脂具有显著改善作用,并可显著减少患者颈动脉斑块,改善患者病情,具有临床诊疗价值。 |
关键词: 阿昔莫司 氯吡格雷 高脂血症 颈动脉斑块 |
DOI:10.13748/j.cnki.issn1007-7693.2020.05.017 |
分类号:R969.4 |
基金项目:河北省卫生计生委医学科学研究项目(20160355) |
|
Effect of Acipimox Combined with Clopidogrel on Blood Lipid and Carotid Plaque in Patients with Hyperlipidemia |
JIANG Aiwen1, DU Peishan2, TANG Jianhua1, SHI Jinzheng1, LIU Yunning1, ZHANG Heming1
|
1.The First Affiliated Hospital of Hebei North Usniversity, Zhangjiakou 075000, China;2.Zhangjiakou First Hospital, Zhangjiakou 075000, China
|
Abstract: |
OBJECTIVE To investigate the clinical effect of acipimox combined with clopidogrel in the treatment of hyperlipidemia and carotid plaque. METHODS Sixty six patients with hyperlipidemia and carotid plaque were randomly divided into acipimox group and acipimox+clopidogrel group. Acipimox group was given acipimox 0.25 g, bid, orally, acipimox+clopidogrel group was given acipimox 0.25 g, bid, orally and clopidogrel 75 mg, qd, orally. Treatment course of 2 groups lasted for 8 weeks. The plasma level of TC, TG, HDL-C, LDL-C, IMT, parameters of hemorheology, TNF-α, IL-1 and IL-6 were observed in 2 groups before and after treatment. RESULTS TC, TG, HDL-C, LDL-C, IMT, parameters of hemorheology, TNF-α, IL-1 and IL-6 had no statistical significance between 2 groups before treatment. TC, LDL-C, carotid plaque area, plasma fibrinogen, TNF-α and IL-6 of 2 groups after treatment were significantly lower than before, and those of acipimox+clopidogrel group were significantly lower than acipimox group(P<0.05). IMT of 2 groups was improved, but no statistical significance between 2 groups compared with before treatment. CONCLUSION Acipimox combined with clopidogrel can significantly improve blood lipids in patients with hyperlipidemia, significantly reduce carotid plaque in patients, and improve the patient’s condition, which has clinical diagnosis and treatment value. |
Key words: acipimox clopidogrel hyperlipemia carotid plaque |